

# Sara Elena Rebutzi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7442484/publications.pdf>

Version: 2024-02-01

42  
papers

629  
citations

567144

15  
h-index

642610

23  
g-index

42  
all docs

42  
docs citations

42  
times ranked

1032  
citing authors

#	ARTICLE	IF	CITATIONS
1	The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1063-1074.	3.3	24
2	Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223. <i>Annals of Nuclear Medicine</i> , 2022, 36, 373-383.	1.2	6
3	Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210795.	1.4	10
4	Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives. <i>Cancers</i> , 2022, 14, 1245.	1.7	19
5	Beyond the Prognostic Value of 2-[18F]FDG PET/CT in Prostate Cancer: A Case Series and Literature Review Focusing on the Diagnostic Value and Impact on Patient Management. <i>Diagnostics</i> , 2022, 12, 581.	1.3	4
6	Prognostic Value of the BIO-Ra Score in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223 after the European Medicines Agency Restricted Use: Secondary Investigations of the Multicentric BIO-Ra Study. <i>Cancers</i> , 2022, 14, 1744.	1.7	7
7	Beyond BRCA: The Emerging Significance of DNA Damage Response and Personalized Treatment in Pancreatic and Prostate Cancer Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4709.	1.8	13
8	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 727.	1.1	3
9	The prognostic role of nephrectomy in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with immunotherapy according to the novel prognostic Meet-URO score: Subanalysis of the Meet-URO 15 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4535-4535.	0.8	0
10	The prognostic value of peripheral blood inflammatory indices early variation in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with nivolumab ( <sup>18</sup> F-Meet-URO analysis).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4534-4534.	0.8	0
11	Adherence to oral treatments in elderly patients with advanced prostate cancer: The ADHERE study, a prospective trial of the Meet-URO network.. <i>Journal of Clinical Oncology</i> , 2022, 40, 12044-12044.	0.8	2
12	Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression. <i>Cancers</i> , 2021, 13, 1300.	1.7	10
13	Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2625.	1.8	38
14	Neuroendocrine Differentiation of Prostate Cancer Is Not Systematically Associated with Increased 18F-FDG Uptake. <i>Diagnostics</i> , 2021, 11, 468.	1.3	6
15	Prognostic role of inflammatory biomarkers from peripheral blood and clinical factors in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with radium-223 (Ra-223) (BIO-Ra-223 study).. <i>Journal of Clinical Oncology</i> , 2021, 39, e17026-e17026.	0.8	0
16	Immunotherapy retreatment: case report, review of the literature and proposal for the definition of different scenarios. <i>Immunotherapy</i> , 2021, 13, 645-652.	1.0	2
17	Rare anti-VEGFR therapy-induced toxicity and long-term response to immunotherapy in a rare non-clear cell renal cell carcinoma patient. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	0.7	1
18	Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110196.	1.4	36

#	ARTICLE	IF	CITATIONS
19	Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence. <i>Cancers</i> , 2021, 13, 5517.	1.7	8
20	Durable response after immunotherapy discontinuation for delayed and severe immune-related adverse event: a case report. <i>Immunotherapy</i> , 2021, 13, 1379-1386.	1.0	3
21	Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 169-185.	1.5	21
22	Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 146, 102820.	2.0	53
23	Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour. <i>Anti-Cancer Drugs</i> , 2020, 31, 80-84.	0.7	7
24	Abscopal effect after hypofractionated radiotherapy in metastatic renal cell carcinoma pretreated with pazopanib. <i>Immunotherapy</i> , 2020, 12, 869-878.	1.0	4
25	Adjuvant Chemotherapy for Stage II Colon Cancer. <i>Cancers</i> , 2020, 12, 2584.	1.7	27
26	Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy. <i>Immunotherapy</i> , 2020, 12, 1139-1148.	1.0	6
27	The Prognostic Role of Baseline Metabolic Tumor Burden and Systemic Inflammation Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223: A Proof of Concept Study. <i>Cancers</i> , 2020, 12, 3213.	1.7	22
28	Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDia study. <i>Immunotherapy</i> , 2020, 12, 151-159.	1.0	16
29	EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non-Small-cell Lung Cancer Treated With Immunotherapy. <i>Clinical Lung Cancer</i> , 2020, 21, 365-377.e5.	1.1	44
30	Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: Survival across disease and treatment subgroup analysis and review of the literature. <i>Molecular and Clinical Oncology</i> , 2019, 10, 58-66.	0.4	10
31	Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice. <i>Oncology Letters</i> , 2019, 17, 1467-1476.	0.8	27
32	Advances in the prediction of long-term effectiveness of immune checkpoint blockers for non-small-cell lung cancer. <i>Immunotherapy</i> , 2019, 11, 993-1003.	1.0	16
33	The Optimal Duration of Adjuvant Therapy for Stage III Colon Cancer: the European Perspective. <i>Current Treatment Options in Oncology</i> , 2019, 20, 8.	1.3	4
34	Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1283-1289.	1.1	21
35	Anti-angiogenesis boosts chemo-immunotherapy in patients with EGFR mutations or baseline liver metastases: insights from IMpower150 study. <i>Translational Cancer Research</i> , 2019, 8, S612-S617.	0.4	10
36	Wide and Cystic Brain Metastases Reveal RET-Rearranged Non-Small-Cell Lung Cancers. <i>JCO Precision Oncology</i> , 2019, 3, 1-7.	1.5	3

#	ARTICLE	IF	CITATIONS
37	EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort. <i>Cancers</i> , 2019, 11, 1954.	1.7	57
38	Therapeutic approach in glioblastoma multiforme with primitive neuroectodermal tumor components: Case report and review of the literature. <i>Oncology Letters</i> , 2018, 15, 6641-6647.	0.8	15
39	Immunotherapy beyond progression in advanced renal cell carcinoma: a case report and review of the literature. <i>Immunotherapy</i> , 2018, 10, 1123-1132.	1.0	9
40	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study. <i>Immunotherapy</i> , 2018, 10, 1229-1239.	1.0	38
41	Evaluation of the efficacy of cisplatin+etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC. <i>ERJ Open Research</i> , 2017, 3, 00128-2016.	1.1	20
42	Neoadjuvant Chemotherapy in Neuroendocrine Bladder Cancer: A Case Report. <i>American Journal of Case Reports</i> , 2016, 17, 248-253.	0.3	7